Comparative Pharmacology
Head-to-head clinical analysis: CRESEMBA versus GRISEOFULVIN ULTRAMICROSIZE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CRESEMBA versus GRISEOFULVIN ULTRAMICROSIZE.
CRESEMBA vs GRISEOFULVIN, ULTRAMICROSIZE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isavuconazole, the active moiety of CRESEMBA, inhibits fungal cytochrome P450-dependent 14-alpha-demethylase, thereby blocking the conversion of lanosterol to ergosterol, disrupting fungal cell membrane synthesis and function.
Binds to tubulin, disrupting microtubule function and inhibiting fungal cell mitosis; deposited in keratin precursor cells, making keratin resistant to fungal invasion.
200 mg intravenously every 8 hours for the first 48 hours (6 doses), then 200 mg intravenously once daily; or 200 mg orally three times daily for the first 48 hours (6 doses), then 200 mg orally once daily.
250-375 mg orally once daily or 500-750 mg orally once daily for severe infections.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) after oral administration, supporting once-daily dosing; steady-state achieved by Day 4-5.
9-24 hours (mean 15 hours); prolonged in liver disease.
Fecal: ~76% (primarily as unchanged drug); Renal: <1% (unchanged); Biliary: Not a major route; Metabolism via CYP3A4 to inactive metabolites eliminated fecally.
Renal (<1% unchanged); fecal (36% as metabolites); tissue deposition may persist for weeks.
Category C
Category D/X
Antifungal
Antifungal